Dr. Ravi Rao

Dr. Rao joins Sitryx from Swedish Orphan Biovitrum, where he served as Head of Research and Development and Chief Medical Officer leading the development and of several medicines in rare diseases across immunology and haematology. Prior to that, he was Chief Medical Officer of Aeglea Biotherapeutics, a company specialising in rare metabolic diseases. Previously, he held several senior positions in R&D at GlaxoSmithKline working in immunology and specialty medicines and was a Group Medical Director at Roche working in immunology development. Ravi was an academic physician-scientist at Imperial College (London) and is a Member of the Royal College of Physicians, London and an Honorary Member of the Faculty of Pharmaceutical Medicine. He received his MB. BChir from Cambridge University and his Ph.D. in vascular biology from Imperial College, completing a postdoctoral fellowship at Harvard Medical School. He is also an independent board director of DBV Technologies. Ravi will be combining his role at Sitryx with a role at Oxford Biomedica.